Englander Institute for Precision Medicine

Publications

Found 25 results
Author Title Type [ Year(Asc)]
Filters: Author is Buqué, Aitziber  [Clear All Filters]
2024
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Preface.. Methods Cell Biol. 185:xvii-xxiv.
2023
Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, Lehmann CHK, Pan H, Paulhan N, Amon L et al..  2023.  BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.. Cancer Discov. 13(11):2448-2469.
Klapp V, Buqué A, Bloy N, Sato A, Yamazaki T, Zhou XKathy, Formenti SC, Galluzzi L, Petroni G.  2023.  Cellular senescence in the response of HR breast cancer to radiotherapy and CDK4/6 inhibitors.. J Transl Med. 21(1):110.
Guilbaud E, Spada S, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Aretz A, Buqué A, Yamazaki T, Demaria S et al..  2023.  Quantitative assessment of mitophagy in irradiated cancer cells.. Methods Cell Biol. 174:93-111.
2022
Álvarez-Abril B, Bloy N, Galassi C, Sato A, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Buqué A, Galluzzi L et al..  2022.  Cytofluorometric assessment of acute cell death responses driven by radiation therapy.. Methods Cell Biol. 172:17-36.
Jiménez-Cortegana C, Klapp V, Bloy N, Galassi C, Sato A, Yamazaki T, Buqué A, Galluzzi L, Petroni G.  2022.  Cytofluorometric assessment of cell cycle progression in irradiated cells.. Methods Cell Biol. 172:1-16.
Hu Y, Bloy N, Elemento O, Buqué A.  2022.  Nicotinamide drives T cell activation in the mammary tumor microenvironment.. J Transl Med. 20(1):251.
Clement CC, Osan J, Buqué A, Nanaware PP, Chang Y-C, Perino G, Shetty M, Yamazaki T, Tsai WLi, Urbanska AM et al..  2022.  PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.. Sci Immunol. 7(74):eabl3795.
Sato A, Bloy N, Galassi C, Jiménez-Cortegana C, Klapp V, Aretz A, Guilbaud E, Yamazaki T, Petroni G, Galluzzi L et al..  2022.  Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis.. Methods Cell Biol. 172:115-134.
Galassi C, Ruan Y, Sato A, Jiménez-Cortegana C, Klapp V, Bloy N, Guilbaud E, Petroni G, Buqué A, Galluzzi L et al..  2022.  RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells.. Methods Cell Biol. 172:145-161.
Petroni G, Buqué A, Coussens LM, Galluzzi L.  2022.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.. Nat Rev Drug Discov. 21(6):440-462.
2021
Sato A, Buqué A, Yamazaki T, Bloy N, Petroni G, Galluzzi L.  2021.  Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells.. STAR Protoc. 2(2):100488.
Petroni G, Buqué A, Zitvogel L, Kroemer G, Galluzzi L.  2021.  Immunomodulation by targeted anticancer agents.. Cancer Cell. 39(3):310-345.
Buqué A, Galluzzi L, Kroemer G.  2021.  Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy.. Mol Cell Oncol. 8(1):1868266.
Yamazaki T, Wennerberg E, Hensler M, Buqué A, Kraynak J, Fucikova J, Zhou XKathy, Sveinbjørnsson B, Rekdal Ø, Demaria S et al..  2021.  LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.. Oncoimmunology. 10(1):1962592.
Buqué A, Perez-Lanzón M, Petroni G, Humeau J, Bloy N, Yamazaki T, Sato A, Kroemer G, Galluzzi L.  2021.  MPA/DMBA-driven mammary carcinomas.. Methods Cell Biol. 163:1-19.
Buqué A, Bloy N, Kroemer G, Galluzzi L.  2021.  Possible mechanisms of cancer prevention by nicotinamide.. Br J Pharmacol. 178(10):2034-2040.
Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, Formenti SC, Galluzzi L.  2021.  Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer.. Clin Cancer Res. 27(7):1855-1863.
Buqué A, Galluzzi L, Montrose DC.  2021.  Targeting Serine in Cancer: Is Two Better Than One? Trends Cancer. 7(8):668-670.
2020
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G.  2020.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.. Nat Rev Clin Oncol. 17(12):725-741.
Yamazaki T, Kirchmair A, Sato A, Buqué A, Rybstein M, Petroni G, Bloy N, Finotello F, Stafford L, Manzano ENavarro et al..  2020.  Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy.. Nat Immunol. 21(10):1160-1171.
Buqué A, Bloy N, Petroni G, Kroemer G, Galluzzi L.  2020.  NK cells beat T cells at early breast cancer control.. Oncoimmunology. 9(1):1806010.
Yamazaki T, Buqué A, Ames TD, Galluzzi L.  2020.  PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.. Oncoimmunology. 9(1):1721810.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.